Visit Us at These Conferences!

By | Uncategorized

If your travel schedule includes any of these conferences, stop by for a visit! We’ll be speaking at and attending the following events this summer and fall:

AVMA Convention

July 13 – 17, 2018 | Denver, CO

Steven Harrington, PhD will attend and present “Islet and Stem-Cell Transplantation Therapies for Diabetes in Pets” for continuing education credit on July 14th at 8:00 a.m.
Learn more:


2018 NAVRMA Conference

September 6 – 8, 2018 | Sacramento, California

Likarda is proud to serve as a Gold Sponsor of the 2018 NAVRMA Conference. This year’s “New Frontiers in Regenerative Medicine” is exciting and this year’s presenters are sure to push the boundaries of what can be achieved.
Learn more:


AAPS PharmSci360
November 4 – 7 | Washington DC

We’re excited to participate in the 2018 AAPS PharmSci360 as they try out a new meeting format that anticipates a gathering of more than 7,000 attendees from around the globe.
Learn more:


Likarda’s Proprietary 3D Cluster Technology, the CC Microplate™, is Now Available for Purchase

By | News & Media, Uncategorized

CC Microplate from LikardaA chemical’s toxicity to humans is one of the leading causes for promising, new drugs to fail. Often, a drug can show positive results in improving one condition, yet have toxic effects on other human organs. Until recently, researchers’ ability to test how human and animal cells respond to a drug was limited to the confines of a two-dimensional petri dish.

Though widely used, 2D testing is far from ideal because this method cannot accurately predict cells’ reaction given that, in the body, cells attach to one another and move three dimensionally. In addition, valuable time and expense are wasted testing a new drug in two dimensions only to have it fail; those same resources could be allocated sooner to the next promising option. After all, curing diseases such as diabetes and cancer is a race against time.

The limitations of two-dimensional testing were overcome when researchers discovered a way to create and study small 3D structures, miniaturized organ-like cell clusters. Yet this too was not without challenges since 3D cells are hard to work with and very complicated.

Likarda Invented the CC Microplate to Enhance Miniature 3D Cell Structure Formation
Likarda dramatically advanced 3D cluster technology by inventing its CC Microplate, allowing life-saving treatments to go to market faster and more affordably. These patented CC Microplates can produce and test 200,000 clusters of cells in the same amount of space that traditional microplates form and test 384 cell clusters, which saves significant time and money. Cell clusters formed in the CC Microplate can be used for:

  • Drug testing
  • Developing cell-based transplantations
  • Regenerative medicine

The CC Microplate can be used with screening methods ranging from biochemical assays to phenotypic or high content screening.

The CC Microplate Improves Prediction of the Body’s Response to a Drug
The CC Microplate gives you the ability to form cell clusters from different tissues and populations, including those specific to age, sex, species, and breed. Cell clusters formed in the CC Microplate have a low diffusion barrier and are in close proximity so they can attach and react naturally to each other, as well as the drug with which they’re being tested. This results in better prediction of the body’s response. For ease of use, cell clusters can even be made from cryopreserved cells.

The  CC Microplate is Vastly More Efficient Than Other Microplates
Using this proprietary cell culture system can give you an advantage over your competitors by offering a truly scalable solution with vast applicability. Cell clusters, both animal and human, developed in the microplate are uniform in size and can be maintained for longer time periods. Likarda’s CC Microplate is currently available in a 384-well plate format.  This SLAS-compliant format can be readily integrated into the lab and works with existing automated equipment and methodologies.

Being the first to market with your drug discovery is critical to improving health outcomes for humans and animals and establishing market share. Move forward confidently by using Likarda’s CC Microplate in your 3D cell research.

Contact us for more information on purchasing the CC Microplate.

Understanding CRO 3.0

By | News & Media, Uncategorized | No Comments

Understanding the past, present and future roles of CROs in early phase drug discovery

As the race is constant to bring new drugs to market, pharmaceutical and nutraceutical companies and science entrepreneurs turn to contract research organizations (CROs) to provide or supplement research processes. This puts an emphasis on providing pharma and entrepreneurs with custom assays, tools and information that improve their workflow efficiency and speed to market. This article examines how CROs influence the research environment and how they can alter their roles to support pharma and science entrepreneurs in intense market competition, reducing the exorbitant time and cost associated with early phase drug discovery. It explores the roles of CROs’ progression in helping pharma and entrepreneurs move confidently forward from the early discovery phase in the past, now and in the future. Read More